N/A
Completed N=100
Prospective, Multi-center, Single-arm Study to Assess the Safety of Retrieval of the Recovery G2 Filter.
Chronic Obstructive Pulmonary Disease · Venous Thromboembolic Disease
Source: ClinicalTrials.gov NCT00556426 ↗
Enrolled (actual)
100
Serious AEs
6.0%
Results posted
May 2011
Primary outcomePrimary: Technical Success (Retrieval) — 58 participants
Summary
This study was designed to assess the safety of retrieval of the Bard Recovery® G2® Filter System. The G2 filter is an FDA-cleared device for inferior vena caval interruption in patients with pulmonary thromboembolism.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Technical Success (Retrieval) |
58 | — |
| PRIMARY Clinical Success (Retrieval) |
57 | — |
| PRIMARY Percentage of Participants With Adverse Events Through 30 Days Post Retrieval |
14.8 | — |
| SECONDARY Filter Migration > 2cm |
12.2 | — |
| SECONDARY Incidence of Filter Fracture |
1 | — |
Eligibility Criteria
Inclusion Criteria
- The patient is at temporary , increased risk of pulmonary embolism requiring caval interruption
Exclusion Criteria
- The patient has implanted filter in the IVC or superior vena cava (SVC)
- The patient has a duplicated or left-sided IVC
- The patient has a known untreatable or uncontrollable malignancy
- The patient has severe spinal deformity
- The patient has a creatinine > 2.0 mg/dl
- The patient has a life expectancy of < 6 months
Data sourced from ClinicalTrials.gov (NCT00556426). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.